FEB 05, 2019 9:22 AM PST

Proposed New Criteria For Diagnosing Parkinson's

WRITTEN BY: Amy Loriaux

A new review published in the Journal of Parkinson’s Disease suggests that our previous diagnostic criteria for Parkinson's Disease (PD) is inadequate and should be revised. This revised criteria would involve examining patients for prodromal symptoms associated with the disease. Prodromal symptoms are symptoms that are non-PD-like but have a high rate of occurrence in individuals that go on to develop PD. Earlier detection of these symptoms could promote earlier treatment and better outcomes.

Photo source: UnSplash.com

What constitutes prodromal symptoms have been debated, however, the typical symptoms of prodromal PD are mood disorders, autonomic disturbances, cognitive impairment, and sleep disturbances. Other symptoms that have been shown to correlate with a future diagnosis of PD are hyposmia, constipation, and idiopathic REM Sleep Disorder. These symptoms present themselves before the classic motor symptoms that are currently used to diagnose PD (bradykinesia, tremor, rigidity, and postural instability).

The authors of the present review suggest that prodromal PD can last as long as years to decades. This, according to the authors Drs. Daniela Berg, MD, of the Christian-Albrechts-University of Kiel, Germany, and Ronald B. Postuma, MD, MSc, of Montreal General Hospital, suggests that non-motor and subtle motor symptoms may indicate a slow spreading PD pathology. Essentially, PD may not start at the level of the substantia nigra but spread to this area during the prodromal phase. Unfortunately, even the classical motor-based diagnosis is not definitive. To get an absolute diagnosis of PD one has to confirm it with an autopsy.

The authors of the review advocate a new system of diagnostics, which includes an acceptance that prodromal symptoms are actually signs of PD. They also recommend a closer look at the increasing data pointing to certain risk factors and correlate them to imaging and histopathological findings. Finally, they implore for more longitudinal studies that observe conversion to PD in cohorts of individuals with different combinations of risk and prodromal markers. The main idea is to find more diagnostic criteria and link it to current imaging methods to find where in the brain certain changes are taking place. Furthermore, their goal is to screen for legitimate prodromal symptoms so that they can be addressed in the clinician's office.

Photo source: UnSplash.com

Prodromal symptoms are not the same as pre-clinical symptoms for PD. Pre-clinical refers to a stage where no PD-related symptoms are present and the diagnosis of PD has not been declared. The prodromal period, however, begins before the loss of dopamine cells in the substantia nigra that are necessary for movement. This suggests that PD is a slowly spreading neurological disease which may even start outside of the brain. The gut has been suggested as a candidate. The olfactory system may also play a role. Essential, PD may start elsewhere and slowly encompass much of the nervous system.

Thus, if clinicians and scientists accept legitimate prodromal symptoms to diagnose PD, this will lead to earlier detection and earlier treatment. Yet, in doing so, they will have to accept the idea of PD as a slowly progressive neurological disorder with a possible etiology outside of the brain, if not just the substantia nigra. The concept of PD as a motor-disorder, and waiting for the motor symptoms to arise, could shave off years of treatment to either halt the progression of the disease or slow it down. It may be time to start looking for earlier warning signs.

Here is a video from Dr. Wolfgang H. Oertel, MD, Ph.D. from the University of Marburg, Marburg, Germany with further explanation.

Sources: Journal of Parkinson’s Disease, Movement Disorders, European Journal of Neurologyhttps://en.wikipedia.org/wiki/Hyposmia, Journal of Neurology

About the Author
  • I currently work at a small CRO involved in clinical trial management.
You May Also Like
NOV 19, 2019
Drug Discovery & Development
NOV 19, 2019
Psychedelic DMT Creates Vivid Waking Dream State in Brain
In a new study, scientists at Imperial College London investigated how powerful psychedelic dimethyltryptamine (DMT) alters the brain’s electrical ac...
DEC 04, 2019
Neuroscience
DEC 04, 2019
Antibiotic Usage May Cause Parkinson's, Study Finds
A study from Helsinki University Hospital, Finland suggests that excessive usage of certain antibiotics may increase one’s risk of developing Parkins...
DEC 04, 2019
Neuroscience
DEC 04, 2019
Single Dose Ketamine Could Rewire Alcohol, Drug Dependance
Presentation by Tobias Stephenson about previous research exploring ketamine as an addiction treatment.    Researchers at University College Lond...
JAN 19, 2020
Neuroscience
JAN 19, 2020
New Proteins Found in the Optical Processing of Lazy Eyes
Ophthalmology – Amblyopia: By Christine Law M.D.   Researchers in the Bear Lab at the Massachusetts Institute of Technology found surprising con...
JAN 20, 2020
Neuroscience
JAN 20, 2020
Ovarian Cancer Protein Accelerates Alzheimer's Neurodegeneration
Around 21,000 people in the US are diagnosed with ovarian cancer every year, while an estimated 5.8 million Americans have Alzheimer’s. Now, research...
FEB 13, 2020
Cell & Molecular Biology
FEB 13, 2020
Study of Early-Onset Parkinson's Reveals Potential Therapeutic
Around 500,000 Americans are diagnosed with Parkinson's disease every year, and the rate of the disease is rising....
Loading Comments...